EMA Recommends Marketing Authorization for Ascendis Pharma's TransCon CNP in EU
- Reports
- 3
- Developments
- 1
- Repetition
- 67%
New informationRepeats or wire copies
What happened
The Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion recommending marketing authorization for TransCon CNP (navepegritide) in the European Union. The drug is intended for treating achondroplasia in children two years of age and older. The final decision from the European Commission is expected during the fourth quarter of 2026.
From manilatimes.net
Why it matters
The positive opinion from the European Medicines Agency is a critical step toward market access for the drug in the European Union. The European Commission reviews and uses these scientific opinions to issue final market authorization decisions.
From manilatimes.net
Who's involved
- European CommissionReviews and uses scientific opinions from the EMA to issue final market authorization decisions.
- European Medicines AgencyAdopted a positive opinion recommending marketing authorization for TransCon CNP in the European Union.
- NasdaqThe stock exchange where Ascendis Pharma A/S is listed.
- FDACoordinates with the EMA on global standards and drug evaluation processes.
Possible ripples
Who this could reach next, traced step by step from the reporting. Possibilities worth considering, not forecasts.Keep exploring
The entities involved
-
European Commission
executive branch of the European Union
-
European Medicines Agency
highest regulatory authority on medicines in the European Union